ASCO 2026 Abstract 3143 (Preview Today): GLP-1 RAs Reduce Metastatic Progression 38-50% in Four Obesity-Related Cancers — 12,112-Patient Real-World Analysis
A real-world data analysis previewed at ASCO's May 26 embargoed press briefing compared GLP-1 receptor agonists against DPP-4 inhibitors (gliptins) across 12,112 patients with seven obesity-related cancers. For four of the seven — lung, breast, colorectal, and liver — patients on GLP-1s were 38% to 50% less likely to progress to stage IV cancer than patients on gliptins. Specific metastasis rates: lung 10% (GLP-1) vs 22% (gliptin), breast 10% vs 20%, colorectal 13% vs 22%, liver 19% vs 28%. High tumor GLP-1 receptor expression was associated with a 33% lower risk of death across all seven cancer types; the association was particularly strong in breast cancer (45% lower mortality). The data reframes GLP-1 therapy as a candidate cancer-prevention modality alongside the established cardiometabolic indications. Abstract 3143 will be presented at the May 29-June 2 ASCO Annual Meeting in Chicago.